Study study type PathologyT1T0Patientssample sizesROB Results

metastatic glioblastoma (mGB) - 1st line (L1) metastatic glioblastoma (mGB) - 1st line (L1)

versus bevacizumab
nivolumab alone
Checkmate 143, 2020
  NCT02017717
RCTmetastatic glioblastoma (mGB) - 1st line (L1)nivolumabbevacizumabpatients with recurrent glioblastoma or gliosarcoma after first-line treatment with radiotherapy and temozolomide184 / 185some concern
inconclusive
  • inconclusive 4 % increase in deaths (OS) (PE)
  • statistically significant 97 % increase in progression or deaths (PFS)
  • statistically significant 72 % decrease in objective responses (ORR)